RBC Capital Maintains Sector Perform on Lakefront Biotherapeutics, Lowers Price Target to $26
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Brian Abrahams maintains Lakefront Biotherapeutics (NASDAQ:LKFT) with a Sector Perform and lowers the price target from $28 to $26.
RBC Capital analyst Brian Abrahams maintains Lakefront Biotherapeutics (NASDAQ:LKFT) with a Sector Perform and lowers the price target from $28 to $26.